Any new insulin product entering the market will inevitably face severe competition from half a dozen approved insulin products and more on the way. As a newcomer to the field, Flamel Technologies S.A. has an even harder task as it tries to develop its Basulin long-acting human insulin for Types I and II diabetes.

However, FLMLY (Lyon, France) believes that Basulin has two competitive advantages: it's a human insulin with 24-hour duration. And with the marketing muscle of its new partner, long-time insulin player Novo Nordisk A/S, the company thinks it is ready to break